Sunnybrook pioneers the world’s first breast cancer treatment that implants small beads of palladium, a low-dose radioactive material, in patients in a one-day outpatient technique.
A new system is set up for stroke patients in which ambulances bypass the local hospital to transport all patients judged to be eligible for the drug tPA (within three hours of onset of stroke) to Sunnybrook or one of the other two regional stroke centres.
Researchers report that patients treated with high-dose radiation for head and neck cancer in the morning have a lower risk of developing damage to the mouth and throat, than do patients who are treated in the afternoon, the first such study.
Scientists predict for the first time, using neuropsychological testing, which study participants will develop Alzheimer's disease within five or 10 years.
Sunnybrook research finds that premenopausal women with HER2-positive breast cancer have better survival and lower recurrence rates when treated with anthracycline-based chemotherapy.
Neuroimaging scientists discover the CT angiography “spot sign,” the first practical imaging method to identify the highest-risk stroke patients with bleeding into the brain. The finding has been adopted worldwide and forms the basis of a new emergency treatment protocol for stroke patients.
Sunnybrook leads an international study that shows magnetic resonance imaging can improve the detection of hidden cancers in the opposite breast of women diagnosed with unilateral breast cancer.
Discovery: the expression of a certain gene predicts which prostate cancer patients are at highest risk and therefore most likely to benefit from treatment.
Sunnybrook launches the SHARE (Sexual Health and Rehabilitation) Clinic.
Sunnybrook brain scientists are the first in the world to find and identify the fundamental waveform of dreaming sleep, providing possible links to learning and memory, potentially important for conditions such as stroke.
The Canadian ALS Network becomes the first organized national network dedicated to developing and conducting clinical trials testing new ALS therapies. CALS continues under the direction of Sunnybrook Brain Sciences leaders.
Sunnybrook researchers through the Crolla Research Unit and the Canadian Brain Tumour Consortium network, lead the world’s largest clinical trial testing the use of daily (metronomic) chemotherapy in relapsed brain cancer, establishing this therapy as the global standard for treatment.
Researchers provide the first evidence showing what the H1N1 virus looks like and that it hits younger and healthier people harder. This enables hospitals in Canada and around the world to prepare for and treat "high-risk" patients effectively.
Sunnybrook’s Schulich Heart Centre is the first in Toronto to perform minimally invasive, beating-heart bypass surgery.
Sunnybrook leads research in circadian rhythms and “clock genes,” illustrating that the timing of cancer treatment is important.
Sunnybrook brain scientists are able to increase dreaming sleep by stimulating the area of the brain responsible for P-waves, advancing research using deep-brain recordings and stimulation to understand sleep, cognition and neurodegenerative disorders better.
Sunnybrook launches the world's first dual-site-focused ultrasound surgery centre and tests the "scalpel-less" removal of uterine fibroids through high-intensity ultrasound, guided by MRI. Researchers in the centre will apply the technology, invented and commercialized by a Sunnybrook Research Institute scientist, to patients with breast, bone, head and neck, and rectal cancer.
Researchers discover that a commonly prescribed antidepressant, paroxetine, interferes with tamoxifen therapy in women with breast cancer, and that other antidepressants of the same class do not.
Drano for Arteries: Schulich Heart Centre leads the first small clinical trial of a new treatment (investigational drug MZ-004) for patients with blocked coronary arteries. The findings are poised to change the way patients are treated, with a large multi-site, international clinical trial to begin later in 2013.
Canada-first Rapid Results Prostate Biopsy Clinic launches to provide men with prostate cancer diagnosis within 72 hours versus the standard two- to three-week wait.
Sunnybrook leads the first study comparing blood vessel functioning of teens with bipolar disorder and teens who are healthy, to better understand the link between bipolar disorder and heart disease.